🚀 RECENT AI SUCCESS

Our AI successfully predicted the gap for $EXPN.L and executed a SELL strategy, securing a +27.05% net profit.

UPGRADE TO SEE LIVE SIGNALS

$KLRS

Kalaris Therapeutics Inc

United StatesUNITED STATES
FREE PREVIEW
AVG HISTORICAL GAP-1.85%
MAX GAP RECORD-4.14%
PREMIUM
AI ACCURACY RATE
92.4%
Unlock AI Insights 🔓

LAST 10 EARNINGS GAPS (%)

VOLATILITY & BIAS PROFILE

AVG VOLATILITY2.0%
Bullish Gaps
Bearish Gaps
Neutral

Intelligence Brief

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ. Read full dossier

CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL